Dr. Douglas C. Wolf, MD

Medicare patients and services

Medicare patients, 2024

111

Services billed

2,150

Patients’ average age

73

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 14 companies reported 129 payments worth $98,524 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Georgia →

Industry-funded research

Named as a principal investigator on 15 industry-funded studies in 2025, from 6 companies. The companies reported $605,092 in research payments for these studies, mostly to the institutions running them.

• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC)
  Janssen Research & Development, LLC
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)
  Janssen Research & Development, LLC
• A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
  AbbVie Inc. · Active, not recruiting · NCT03105102
• A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohns Disease
  E.r. Squibb & Sons, L.l.c.
• A multicenter randomized doubleblind parallelgroup study to assess the efficacy and safety of oral etrasimod as induction and maintenance therapy for moderately to severely active crohns disease
  Pfizer Inc.
• M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease
  AbbVie Inc.
• A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
  E.r. Squibb & Sons, L.l.c.
• A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohns Disease
  E.r. Squibb & Sons, L.l.c.
• An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
  Celgene Corporation · Terminated · NCT03467958
• A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease
  AbbVie Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Gastroenterology clinicians in Atlanta

• Girish Anand, M.D.
• Naveen Anand, M.D.
• Frank A. Anania, M.D.
• Harold Asher, MD
• Mahmoud B. Barrie, MD
• Jasna I. Beard, MD
• William L. Boddie, MD
• David S. Brandenburg, MD